Please check your internet connection and try again.
## Hepamerz (l-Ornithine l-Aspartate)
### Overview
L-ornithine L-aspartate (LOLA) is a combination of two amino acids used in the management of hepatic encephalopathy. It is believed to reduce ammonia levels by promoting its detoxification in the liver and kidneys.
### Primary Indications
* Treatment of hepatic encephalopathy (overt and subclinical) associated with chronic liver disease.
### Adult Dosing
* **Oral:** Typically 6 to 18 grams per day, divided into 2-3 doses.
* **Intravenous (IV):** Typically 5 grams administered every 8 hours, diluted in a suitable infusion fluid. Dosing can be adjusted based on clinical response and ammonia levels, but specific maximums are not well-established and should be guided by local protocols and patient response.
### Pediatric Dosing
* Limited data available for pediatric use. Dosing should be individualized by a specialist based on age, weight, and clinical condition.
### Dose Adjustments
* No specific dose adjustments are typically required for renal or hepatic impairment, as the drug is metabolized and excreted through hepatic and renal pathways, respectively. However, caution is advised in severe renal dysfunction.
### Contraindications
* Severe renal insufficiency.
* Hypersensitivity to l-ornithine or l-aspartate.
### Adverse Effects
* Gastrointestinal disturbances (nausea, vomiting, abdominal pain, diarrhea) are the most common.
* Rarely, rash, itching, or headache may occur.
### Key Drug Interactions
* No significant drug interactions are well-documented.
### Monitoring
* Serum ammonia levels (baseline and periodically during treatment).
* Clinical assessment of hepatic encephalopathy symptoms (e.g., mental status, confusion, asterixis).
* Renal function (especially with high doses or in patients with pre-existing renal issues).
### Clinical Pearls
* LOLA is most effective when used in conjunction with a comprehensive management strategy for liver disease, including dietary protein restriction (if appropriate) and treatment of the underlying liver condition.
* Oral administration should ideally be taken with meals to minimize gastrointestinal upset.
* IV administration offers faster absorption and may be preferred in acute settings or for patients unable to tolerate oral intake.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*
